SPPAM
ITCI

Summit Partners Public Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Summit Partners Public Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50,000
Closed -$2.71M – 179
2023
Q1 		$2.71M Buy
+50,000
New +$2.42M 0.11% 90

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Partners Public Asset Management's ITCI Position: Q3 2023 in Review

Summit Partners Public Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2023, closing a stake of 84,515 shares — an estimated $5.35M sold.

Summit Partners Public Asset Management first reported a position in ITCI in Q1 2022 and held it in 4 quarters. The position peaked at $14.7M in Q1 2022. 292 funds tracked by Wall St. Rank hold ITCI as of Q3 2023.

  • Summit Partners Public Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2023 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 84,515 Intra-Cellular Therapies Inc. shares in Q3 2023, an estimated $5.35M.
  • Summit Partners Public Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 4 quarters.
  • Summit Partners Public Asset Management's Intra-Cellular Therapies Inc. position peaked at $14.7M in Q1 2022.
  • 292 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2023.

Based on Summit Partners Public Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.